Immune effector cells and antigen presentation pathways

Immune effector cells and antigen presentation pathways represent the integrated biological system responsible for the detection and destruction of non-self or altered-self entities, such as pathogens and tumor cells (NIH, 2024). This system involves the processing of antigens into peptides by proteasomes or endosomes and their presentation on the cell surface via Major Histocompatibility Complex (MHC) molecules (Nature Reviews Immunology, 2017). Effector cells, including CD8+ cytotoxic T lymphocytes and Natural Killer (NK) cells, recognize these presented antigens to initiate targeted cell lysis. In oncology, tumors often evade these pathways by downregulating MHC expression or upregulating inhibitory checkpoints like PD-1, which suppresses effector cell function. Therapeutic strategies such as checkpoint inhibitors and CAR-T cell therapies aim to restore or enhance these pathways to treat cancer (StatPearls, 2023). Conversely, dysregulation leading to overactivity in these pathways is a hallmark of autoimmune diseases and graft-versus-host disease. Because this term describes a broad set of biological processes and multiple cell types rather than a single molecular entity, it is classified as a pathway or system rather than a discrete therapeutic target.

Other names

Antigen processing and presentationImmune effector mechanismsMHC-mediated immunityT-cell activation pathways

Modulation of immune checkpoint signaling (e.g., PD-1/CTLA-4 inhibition), enhancement of antigen recognition by T-cells, and direct activation or engineering of effector cell populations (StatPearls, 2023).